Prolactinomas presenting as primary amenorrhoea and delayed or arrested puberty: response to medical therapy.
Fourteen patients presented with arrested pubertal development associated with prolactin-secreting pituitary tumours; serum prolactin ranged from 4000-104,300 mU/l in the ten females and 920-68,000 in four males. Skull X-ray showed a markedly expanded pituitary fossa in eight patients. CT scan and/or air encephalography showed macroadenomas in nine, of whom seven had large suprasellar extensions to their tumours, yet only five had complained of headache and only two had visual field defects. All were treated with bromocriptine (7.5-60 mg/day) which lowered prolactin substantially in all and into the normal range in 11 (range less than 60-3090, median 105 mU/l). Puberty thereafter progressed spontaneously in 13, but in one patient, whose prolactin did not suppress completely, menarche could be induced only with clomiphene. Anterior pituitary function improved on bromocriptine. In seven patients with macroadenomas, tumour shrinkage into the pituitary fossa was complete and in two others incomplete shrinkage was followed by transsphenoidal hypophysectomy. Seven patients received pituitary irradiation, six after bromocriptine-induced shrinkage and one after transsphenoidal surgery. At follow-up 6 months to 10 years (median 5 years) after presentation, ten remain on bromocriptine with a suppressed serum prolactin, one has a normal prolactin after surgery, and three are off bromocriptine with residual hyperprolactinaemia (418-4680 mU/l). To date, four females have become pregnant and one male has fathered two children. Prolactinomas are an important, albeit rare, cause of arrested puberty and should therefore be sought. Most patients respond well to bromocriptine, with or without pituitary irradiation.
Howlett
T A
TA
Department of Endocrinology, St Bartholomew's Hospital, London, UK.
Wass
J A
JA
Grossman
A
A
Plowman
P N
PN
Charlesworth
M
M
Touzel
R
R
Rees
L H
LH
Savage
M O
MO
Besser
G M
GM
D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000209:etiology*; D001971:Bromocriptine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D010911:Pituitary Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000532:radiotherapy; D015175:Prolactinoma / Q000150:complications* / Q000188:drug therapy / Q000532:radiotherapy; D011628:Puberty, Delayed / Q000209:etiology*
D001971:Bromocriptine